Liver Disease Treatment Market Report by Treatment Type, Disease Type (Hepatitis, Autoimmune Diseases, Non-alcoholic Fatty Liver Disease, Cancer, Genetic Disorders, and Others), End User, and Region 2024-2032
세계 간질환 치료제 시장 규모는 2023년 238억 달러에 달했습니다. 향후 IMARC Group은 2024-2032년까지 5.7%의 연평균 성장률(CAGR)을 보이며 2032년까지 394억 달러에 달할 것으로 예상하고 있습니다.
간은 비타민과 영양소 저장, 혈액 내 유해물질 제거, 체내 화학물질의 적절한 균형 유지 등 중요한 기능을 수행하는 인체의 중요한 기관입니다. 암, 간염, 자가면역질환, 유전성 질환 등이 흔한 간 질환입니다. 이러한 질병은 일반적으로 감염, 유전, 비만, 당뇨병, 면역 체계 이상으로 인해 발생합니다. 간 질환의 치료에 널리 사용되는 방법으로는 백신, 화학요법, 항바이러스제, 면역글로불린, 코르티코스테로이드, 면역억제제 등이 있습니다. 간질환 치료는 콜레스테롤과 호르몬 배설을 돕고 담즙 분비를 증가시키며 효소 활성화를 촉진합니다.
간질환 치료제 시장 동향
간 질환을 포함한 다양한 만성 질환에 취약한 노인 인구가 전 세계적으로 증가하고 있는 것은 시장 성장을 가속하는 주요 요인 중 하나입니다. 식생활 패턴의 변화와 좌식 생활습관의 변화가 시장 성장을 가속하고 있습니다. 또한 고콜레스테롤, 비만, 고혈압, 당뇨병으로 인한 지방간 질환의 유병률 증가는 시장 성장을 가속하고 있습니다. 또한, 바이오 인공간 시장 개척 등 다양한 기술 발전이 시장 성장에 탄력을 받고 있습니다. 이는 재생 간세포를 이용하여 간 기능을 대체하는 것으로, 급성 간부전 환자에게 널리 사용되고 있습니다. 이와 함께 안전하고 효과적이며 B형 간염 바이러스를 억제하고 간경변증과 간세포암의 위험을 줄이는 데 도움이 되는 항바이러스제의 급속한 채택이 시장 성장에 긍정적인 영향을 미치고 있습니다. 이 외에도 연구 개발(R&D) 활동 증가, 의료 산업의 괄목할만한 성장, 공중 보건을 촉진하기위한 다양한 정부 이니셔티브의 시행은 시장에 밝은 전망을 제시하고 있습니다.
본 보고서에서 다룬 주요 질문들
- 2023년 세계 간질환 치료제 시장 규모는?
- 2024-2032년 세계 간질환 치료제 시장의 예상 성장률은?
- 세계 간질환 치료제 시장을 이끄는 주요 요인은?
- 코로나19가 세계 간질환 치료제 시장에 미치는 영향은?
- 세계 간질환 치료제 시장의 치료 유형별 분류는?
- 세계 간질환 치료제 시장의 질병 유형별 분류는?
- 세계 간질환 치료제 시장의 주요 지역은?
- 세계 간질환 치료제 시장의 주요 시장 진출 기업은?
목차
제1장 서문
제2장 조사 범위와 조사 방법
- 조사 목적
- 이해관계자
- 데이터 소스
- 시장 추정
- 조사 방법
제3장 주요 요약
제4장 서론
제5장 세계의 간질환 치료 시장
- 시장 개요
- 시장 실적
- COVID-19의 영향
- 시장 예측
제6장 시장 분석 : 치료 유형별
- 항바이러스제
- 면역억제제
- 백신
- 면역글로불린
- 코르티코스테로이드
- 표적치료
- 화학요법
제7장 시장 분석 : 질환 유형별
- 간염
- 자가면역 질환
- 비알코올성 지방성간질환(NAFLD)
- 암
- 유전성 질환
- 기타
제8장 시장 분석 : 최종사용자별
제9장 시장 분석 : 지역별
- 북미
- 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
- 라틴아메리카
- 중동 및 아프리카
제10장 SWOT 분석
제11장 밸류체인 분석
제12장 Porter의 산업 분석
- 개요
- 바이어의 교섭력
- 공급 기업의 교섭력
- 경쟁 정도
- 신규 진출업체의 위협
- 대체품의 위협
제13장 가격 분석
제14장 경쟁 구도
- 시장 구조
- 주요 기업
- 주요 기업 개요
- Abbott Laboratories
- AbbVie Inc.
- Astellas Pharma Inc.
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Emergent BioSolutions Inc.
- F. Hoffmann-La Roche AG
- Gilead Sciences Inc.
- GlaxoSmithKline plc
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi S.A.
- Takeda Pharmaceutical Company Limited
- Viatris Inc.
The global liver disease treatment market size reached US$ 23.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 39.4 Billion by 2032, exhibiting a growth rate (CAGR) of 5.7% during 2024-2032.
The liver is a vital organ of the human body that performs significant functions, such as storing vitamins and nutrients, removing harmful substances from the blood, and maintaining an adequate balance of chemicals in the body. Cancer, hepatitis, autoimmune diseases, and genetic disorders are some common liver diseases. These diseases are commonly caused by infections, genetics, obesity, diabetes, and immune system abnormalities. Some of the widely used therapeutic techniques for liver diseases include vaccines, chemotherapy, antiviral drugs, immunoglobulins, corticosteroids, and immunosuppressants. Liver disease treatment aids in the excretion of cholesterol and hormones, increases bile production and enzyme activation.
Liver Disease Treatment Market Trends:
The rising geriatric population, which is suspetible to various chronic ailments, including liver disease, across the globe is one of the prime factors driving the growth of the market. The changing dietary patterns and sedentary lifestyles are boosting the market growth. Additionally, the increasing prevalence of fatty liver disease due to high cholesterol, obesity, hypertension (high blood pressure), and diabetes is favoring the market growth. Moreover, various technological advancements, such as the development of the bioartificial liver, are providing an impetus to the market growth. It utilizes regenerated liver cells to replace liver functions and is widely used for acute liver failure patients. In line with this, the rapid adoption of antiviral drugs as they are safe and effective, assist in suppressing the hepatitis B virus, and help in reducing the risk of developing cirrhosis and hepatocellular carcinoma, is positively impacting the market growth. Apart from this, increasing research and development (R&D) activities, significant growth in the healthcare industry, and the implementation of various government initiatives to promote public health are creating a positive outlook for the market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global liver disease treatment market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on treatment type, disease type and end user.
Breakup by Treatment Type:
Antiviral Drugs
Immunosuppressants
Vaccines
Immunoglobulins
Corticosteroids
Targeted Therapy
Chemotherapy
Breakup by Disease Type:
Hepatitis
Autoimmune Diseases
Non-alcoholic Fatty Liver Disease (NAFLD)
Cancer
Genetic Disorders
Others
Breakup by End User:
Hospitals
Ambulatory Surgical Centers
Others
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, AbbVie Inc., Astellas Pharma Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Emergent BioSolutions Inc., F. Hoffmann-La Roche AG, Gilead Sciences Inc., GlaxoSmithKline plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited and Viatris Inc.
Key Questions Answered in This Report
- 1. What was the size of the global liver disease treatment market in 2023?
- 2. What is the expected growth rate of the global liver disease treatment market during 2024-2032?
- 3. What are the key factors driving the global liver disease treatment market?
- 4. What has been the impact of COVID-19 on the global liver disease treatment market?
- 5. What is the breakup of the global liver disease treatment market based on the treatment type?
- 6. What is the breakup of the global liver disease treatment market based on the disease type?
- 7. What is the breakup of the global liver disease treatment market based on the end user?
- 8. What are the key regions in the global liver disease treatment market?
- 9. Who are the key players/companies in the global liver disease treatment market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Liver Disease Treatment Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Treatment Type
- 6.1 Antiviral Drugs
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Immunosuppressants
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Vaccines
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Immunoglobulins
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 Corticosteroids
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
- 6.6 Targeted Therapy
- 6.6.1 Market Trends
- 6.6.2 Market Forecast
- 6.7 Chemotherapy
- 6.7.1 Market Trends
- 6.7.2 Market Forecast
7 Market Breakup by Disease Type
- 7.1 Hepatitis
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Autoimmune Diseases
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Non-alcoholic Fatty Liver Disease (NAFLD)
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Cancer
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Genetic Disorders
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
- 7.6 Others
- 7.6.1 Market Trends
- 7.6.2 Market Forecast
8 Market Breakup by End User
- 8.1 Hospitals
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Ambulatory Surgical Centers
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Others
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 Abbott Laboratories
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.1.4 SWOT Analysis
- 14.3.2 AbbVie Inc.
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.2.3 Financials
- 14.3.2.4 SWOT Analysis
- 14.3.3 Astellas Pharma Inc.
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.3.3 Financials
- 14.3.3.4 SWOT Analysis
- 14.3.4 Bristol-Myers Squibb Company
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.4.3 Financials
- 14.3.4.4 SWOT Analysis
- 14.3.5 Eli Lilly and Company
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.5.3 Financials
- 14.3.5.4 SWOT Analysis
- 14.3.6 Emergent BioSolutions Inc.
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 Financials
- 14.3.6.4 SWOT Analysis
- 14.3.7 F. Hoffmann-La Roche AG
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.7.3 Financials
- 14.3.8 Gilead Sciences Inc.
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.8.3 Financials
- 14.3.8.4 SWOT Analysis
- 14.3.9 GlaxoSmithKline plc
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.9.3 Financials
- 14.3.9.4 SWOT Analysis
- 14.3.10 Merck & Co. Inc.
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
- 14.3.10.3 Financials
- 14.3.10.4 SWOT Analysis
- 14.3.11 Novartis AG
- 14.3.11.1 Company Overview
- 14.3.11.2 Product Portfolio
- 14.3.11.3 Financials
- 14.3.11.4 SWOT Analysis
- 14.3.12 Pfizer Inc.
- 14.3.12.1 Company Overview
- 14.3.12.2 Product Portfolio
- 14.3.12.3 Financials
- 14.3.12.4 SWOT Analysis
- 14.3.13 Sanofi S.A.
- 14.3.13.1 Company Overview
- 14.3.13.2 Product Portfolio
- 14.3.13.3 Financials
- 14.3.13.4 SWOT Analysis
- 14.3.14 Takeda Pharmaceutical Company Limited
- 14.3.14.1 Company Overview
- 14.3.14.2 Product Portfolio
- 14.3.14.3 Financials
- 14.3.14.4 SWOT Analysis
- 14.3.15 Viatris Inc.
- 14.3.15.1 Company Overview
- 14.3.15.2 Product Portfolio
- 14.3.15.3 Financials
